MedTrace Logo

Mycophenolate After Stem Cell Transplant for Systemic Sclerosis

NCT07734012 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-08-07

No results posted yet for this study

Summary

A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible .

We are studying whether a brief course of treatment with MMF after AHSCT will serve to prevent disease relapse.

Conditions

  • Systemic Sclerosis (SSc)

Interventions

DRUG

Mycophenolate Mofetil 1000 mg twice daily

MMF 1000mg p.o. b.i.d. starting at day 90 post-AHSCT and continued for 6 months.

Sponsors & Collaborators

  • The Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant.

    collaborator UNKNOWN

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Nancy Maltez, Dr · The Ottawa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07734012 on ClinicalTrials.gov